R

Retinal Consultants Medical Group | Greenback Lane, Sacramento, CA

Research site
(Unclaimed)
Location
5775 Greenback Lane, Sacramento, California, United States of America

Site insights

Top conditions

Top treatments

Faricimab
KSI-301
Iptacopan
OPL-0401
Aflibercept
AU-011
Tarcocimab
AVD-104
Runcaciguat

Parent organization

This site is a part of Retinal Consultants Medical Group

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 12 total trials

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD)...

Enrolling
Age-Related Macular Degeneration
Drug: Iptacopan (LNP023)
Drug: Placebo

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Enrolling
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling
Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with g...

Enrolling
Geographic Atrophy
Biological: OpRegen
Status recently updated

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Enrolling
Active, not recruiting
Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Drug: Placebo
Drug: OPL-0401 Dose 1

Trial sponsors

Genentech logo
Kodiak Sciences logo
Aura Biosciences logo
A
Bayer logo
Novartis logo
Roche logo
V

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems